Android app on Google Play

Goldman Sachs Removes Pfizer (PFE) from CL-Buy List, AbbVie (ABBV) Added to CL-Buy List

December 3, 2013 8:38 AM EST Send to a Friend
Get Alerts PFE Hot Sheet
Price: $29.19 -0.68%

Rating Summary:
    14 Buy, 7 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 20 | Down: 13 | New: 51
Trade PFE Now!
Join SI Premium – FREE
Goldman Sachs downgraded Pfizer (NYSE: PFE) from Conviction Buy to Buy with a price target of $35.00 (from $34.00). AbbVie (NYSE: ABBV) was raised to Conviction Buy and its price target was raised to $60 (from $57).

"We remove PFE from the CL but maintain our Buy rating and raise our 12-month target price to $35 for 9% upside (12% on a total return basis). We simply see greater upside to ABBV (24%, 27% on a total return basis), which we add to the CL," said analyst Jami Rubin.

"We have long been advocates of the PFE breakup/ spin story, having argued for such a restructuring as early as November 2008. While as previously discussed we continue to expect PFE to move down the path of a full break up by 2017 (announcement likely in 2015/2016), we no longer see our call as out of consensus," continued the analyst.

On AbbVie Rubin said, "With an $18 bn revenue base, ABBV has more pipeline leverage than most other mid-sized biopharma peers and is entering a long period of robust clinical trial read-outs beginning 4Q13. ABBV shares have outperformed its peer group YTD (up 42% vs. large cap pharma peers 27%), but the stock is still perceived as a one-product story. In our view, ABBV is a pharma converging with biotech, with one of the least vetted pipelines in the sector. We believe that with data read outs over the next 6-12 months, there will be greater recognition of ABBV's pipeline, leading to a re-rate of the stock."

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $31.83 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change, Downgrades, Upgrades

Related Entities

Goldman Sachs Conviction Buy List, Goldman Sachs

Add Your Comment